CH601274A5 - 4-phenyl-2-morpholinones - Google Patents
4-phenyl-2-morpholinonesInfo
- Publication number
- CH601274A5 CH601274A5 CH715376A CH715376A CH601274A5 CH 601274 A5 CH601274 A5 CH 601274A5 CH 715376 A CH715376 A CH 715376A CH 715376 A CH715376 A CH 715376A CH 601274 A5 CH601274 A5 CH 601274A5
- Authority
- CH
- Switzerland
- Prior art keywords
- sep
- group
- formula
- acid
- atom
- Prior art date
Links
- PQJKFWVFRHRHDV-UHFFFAOYSA-N 4-phenylmorpholin-2-one Chemical class C1COC(=O)CN1C1=CC=CC=C1 PQJKFWVFRHRHDV-UHFFFAOYSA-N 0.000 title abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical class O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000004593 Epoxy Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 150000005331 phenylglycines Chemical class 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- 239000003849 aromatic solvent Substances 0.000 claims 1
- 238000006482 condensation reaction Methods 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- -1 phenylthiomethyl Chemical group 0.000 abstract description 4
- 230000001315 anti-hyperlipaemic effect Effects 0.000 abstract 1
- 230000000871 hypocholesterolemic effect Effects 0.000 abstract 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- KSLSZOOZWRMSAP-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]oxirane Chemical compound C1=CC(Cl)=CC=C1OCC1OC1 KSLSZOOZWRMSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP50068925A JPS51146478A (en) | 1975-06-06 | 1975-06-06 | Process for preparing new morpholinone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH601274A5 true CH601274A5 (en) | 1978-06-30 |
Family
ID=13387707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH715376A CH601274A5 (en) | 1975-06-06 | 1976-06-04 | 4-phenyl-2-morpholinones |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS51146478A (en)) |
| AT (1) | AT346355B (en)) |
| BE (1) | BE842566A (en)) |
| CH (1) | CH601274A5 (en)) |
| DD (1) | DD125074A5 (en)) |
| ES (1) | ES448561A1 (en)) |
| LU (1) | LU75095A1 (en)) |
| PT (1) | PT65157B (en)) |
| ZA (1) | ZA763334B (en)) |
-
1975
- 1975-06-06 JP JP50068925A patent/JPS51146478A/ja active Granted
-
1976
- 1976-05-31 PT PT65157A patent/PT65157B/pt unknown
- 1976-06-03 AT AT409076A patent/AT346355B/de not_active IP Right Cessation
- 1976-06-03 BE BE167617A patent/BE842566A/xx not_active IP Right Cessation
- 1976-06-04 CH CH715376A patent/CH601274A5/de not_active IP Right Cessation
- 1976-06-04 ZA ZA763334A patent/ZA763334B/xx unknown
- 1976-06-04 ES ES448561A patent/ES448561A1/es not_active Expired
- 1976-06-04 DD DD193205A patent/DD125074A5/xx unknown
- 1976-06-04 LU LU75095A patent/LU75095A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AT346355B (de) | 1978-11-10 |
| JPS5242796B2 (en)) | 1977-10-26 |
| ATA409076A (de) | 1978-03-15 |
| PT65157A (en) | 1976-06-01 |
| ES448561A1 (es) | 1977-07-01 |
| PT65157B (en) | 1977-10-13 |
| LU75095A1 (en)) | 1977-01-24 |
| ZA763334B (en) | 1977-05-25 |
| DD125074A5 (en)) | 1977-03-30 |
| BE842566A (fr) | 1976-10-01 |
| JPS51146478A (en) | 1976-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2807623C2 (de) | 2-Phenoxyphenyl-pyrrolidinderivate, deren Salze, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen | |
| DE3118162C2 (de) | 1-(4-Chlorbenzhydryl)-4-(2,3-bis-hydroxypropyl)-piperazin, dessen Salze, Verfahren zu deren Herstellung und diese Verbindungen enthaltendes Arzneimittel | |
| CH615151A5 (en)) | ||
| DE2517020C3 (de) | N- [l-(3-Trifluormethyl-phenyl)-prop-2-yl] -glycinester, Verfahren zu ihrer' Herstellung und diese Ester enthaltende Arzneimittel | |
| DE1768612A1 (de) | Verfahren zur Herstellung von sehr reinem,pharmazeutisch geeignetem rechtsdrehenden 2,2'-(AEthylendiimin)-di-1-butanoldihydrochlorid | |
| CH601274A5 (en) | 4-phenyl-2-morpholinones | |
| DE2328053B2 (de) | 1,2-bis(4-phenyl-1-piperazinyl)-aethan- derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende therapeutische zubereitungen | |
| DE1445950B2 (de) | 2,6-bis-(hydroxymethyl)-pyridindicarbamat-derivate und verfahren zu ihrer herstellung | |
| DE2521347B2 (de) | Hydroxylsubstituierte 2-Chlor- a -(tertbutylaminomethyD-benzylalkohole, Herstellungsverfahren und Arzneimittel | |
| DE2711149C3 (de) | N-Substituierte[4-Chlor-6-(23-xylidino)-2· pyrimidinyl- thio] essigsäureamide sowie Verfahren zu deren Herstellung | |
| DE1038047B (de) | Verfahren zur Herstellung von N-aminoalkylierten Iminodibenzylen und deren Salzen | |
| DE1817861C3 (de) | N-alkylierte 3,4-Methylendioxymandelsäureamidine und deren pharmakologisch nicht giftige Säureanlagerungssalze und diese enthaltende pharmazeutische Mittel. Ausscheidung aus: 1811804 | |
| CH599947A5 (en) | 4-phenyl-2-morpholinones | |
| DE2511576A1 (de) | Metformin-clofibrat, verfahren zu seiner herstellung und es enthaltendes arzneimittel | |
| DE1695378C (de) | 2 Azetidindione und Verfahren zu ihrer Herstellung | |
| DE763489C (de) | Verfahren zur Herstellung von ª-Aminoaethylestern substituierter Phenylessigsaeuren | |
| DE2557446C2 (de) | 1-(2'-Aroyl-äth-1'-yl)-2-(4''-acetamido-piperazin-1''-yl-methyl)-benzimidazole, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| AT282595B (de) | Verfahren zur herstellung von neuem racemischem oder optisch aktivem (1-2'-nitrilophenoxy)-2-hydroxy-3-isopropylaminopropan und dessen salzen | |
| DE2259517A1 (de) | Verfahren zur herstellung von d-(-)-mepivacain-hydrochlorid | |
| DE2022790C3 (de) | 10-Methyl-5-[ (4-Methylpiperazino)-acetyl J-5,10dihydro-llH-dibenzo [b,e ] [1,4 ] diazepin-11-on, ein Verfahren zu dessen Herstellung sowie dieses enthaltende Arzneimittel | |
| DE1235310B (de) | Verfahren zur Herstellung von Nopinsaeurederivaten | |
| DE3000623A1 (de) | Hydroxypyrrolidinverbindungen | |
| DE1595875C (de) | Phenothiazine und Verfahren zu deren Herstellung | |
| DE1918042C3 (de) | beta,beta,beta-Trichloräthylidenaminderivate | |
| AT282592B (de) | Verfahren zur herstellung von neuem racemischem oder optisch aktivem (1-2'-nitrilophenoxy)-2-hydroxy-3-isopropylaminopropan und dessen salzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |